Well said SF.

I've been extremely optimisitc over the years and got very excited with the post hoc findings. I really thought those findings as well as the independent research done by scientists on retinal and MD would spark the interests of a BP or another partner.

The recent funding was also another vote of confidence by Eastern and Hepalink.

An increase of $50 million in the LOC secured by Eastern would be another vote of confidence. However, there does not appear to be any evidence of any of this.

It will be many years before any revenue is generated. Perhaps something big is in the works in terms of a new partnership. I certainly have no idea about this. The futility analysis could kill apabetalone/RVX or it may pass this hurdle which I understand it as meaning that there is enough safety and efficacy for the trial to continue. That does not mean that apabetalone will make it to market.

I'm not going to be making a down payment on a Rolls at this stage,

GLTA

Happy 4th of July (tomorrow) to our American friends.

Toinv